An overview of vortioxetine

Journal of Clinical Psychiatry

Volumn 75, Issue 12, 2014, Pages 1411-1418

  Schatzberg, Alan F ^a   Blier, Pierre ^b   Culpepper, Larry ^c   Jain, Rakesh ^d   Papakostas, George I ^e   Thase, Michael E ^f  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^f Psychiatric Drug Research R D Clinical Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SEROTONIN TRANSPORTER; VORTIOXETINE; ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; SEROTONIN RECEPTOR; SULFIDE;

ANTIDEPRESSANT ACTIVITY; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; GENERALIZED ANXIETY DISORDER; HEALTH CARE SYSTEM; HUMAN; INSOMNIA; MAJOR DEPRESSION; MEMORY CONSOLIDATION; MENTAL HEALTH; NAUSEA; NEUROTRANSMISSION; NONHUMAN; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; TRANQUILIZING ACTIVITY; WEIGHT GAIN; ANIMAL; DEPRESSIVE DISORDER, MAJOR; DOSE RESPONSE; DRUG EFFECTS; NUMBERS NEEDED TO TREAT; PRIMARY HEALTH CARE; RECURRENT DISEASE;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NUMBERS NEEDED TO TREAT; PIPERAZINES; PRIMARY HEALTH CARE; RECEPTORS, SEROTONIN; RECURRENCE; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SULFIDES;

EID: 84925228287     PISSN: 01606689     EISSN: 15552101     Source Type: Journal    
DOI: 10.4088/JCP.14027ah1     Document Type: Article

References (54)

1. Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data [published online ahead of print July 9, 2014]. Pharmacol Ther.
2. Citrome L. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2014;68(1):60-82.
3. Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry. 2003;53(3):193-203.
4. Millan MJ. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther. 2006;110(2):135-370.
5. Lam DD, Garfield AS, Marston OJ, et al. Brain serotonin system in the coordination of food intake and body weight. Pharmacol Biochem Behav. 2010;97(1):84-91.
6. Halford JC, Harrold JA. 5-HT(2C) receptor agonists and the control of appetite. Handbook Exp Pharmacol. 2012;209(209):349-356.
7. Vanover KE, Davis RE. Role of 5-HT2A receptor antagonists in the treatment of insomnia. Nat Sci Sleep. 2010;2:139-150.
8. Bonaventure P, Kelly L, Aluisio L, et al. Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents. J Pharmacol Exp Ther. 2007;321(2):690-698.
9. Millan MJ. Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. Neurotherapeutics. 2009;6(1):53-77.
10. Mnie-Filali O, Faure C, Lambás-Señas L, et al. Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy. Neuropsychopharmacology. 2011;36(6):1275-1288.
11. Bang-Andersen B, Ruhland T, Jørgensen M, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011;54(9):3206-3221.
12. Mørk A, Montezinho LP, Miller S, et al. Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacol Biochem Behav. 2013;105:41-50.
13. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012;27(4):215-223.
14. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014;17(10):1557-1567.
15. Adell A. Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety. IDrugs. 2010;13(12):900-910.
16. Bidzan L, Mahableshwarkar AR, Jacobsen P, et al. Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial. Eur Neuropsychopharmacol. 2012;22(12):847-857.
17. Baldwin DS, Loft H, Florea I. Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder. Int Clin Psychopharmacol. 2012;27(4):197-207.
18. Mahableshwarkar AR, Jacobsen PL, Chen Y, et al. A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder. Int J Clin Pract. 2014;68(1):49-59.
19. BRINTELLIX (vortioxetine) tablets, for oral use [package insert]. Deerfield, IL; Takeda Pharmaceuticals America, Inc. 2013.
20. Center for Drug Evaluation and Research. Summary Review. Application number: 204447Orig1s000. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2013/204447Orig1s000SumR.pdf.
21. Alvarez E, Perez V, Dragheim M, et al. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012;15(5):589-600.
22. Boulenger J-P, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 2014;29(3):138-149.
23. US Department of Health and Human Services, Agency for Healthcare Research and Quality, Effective Health Care Program. Glossary of terms. http://effectivehealthcare.ahrq.gov/index.cfm/glossary-of-terms/. Accessed July 14, 2014.
24. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5(2):e45.
25. Moncrieff J. Are antidepressants as effective as claimed? no, they are not effective at all. Can J Psychiatry. 2007;52(2):96-97, discussion 102.
26. Fountoulakis KN, Veroniki AA, Siamouli M, et al. No role for initial severity on the efficacy of antidepressants: results of a multi-meta-analysis. Ann Gen Psychiatry. 2013;12(1):26.
27. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303(1):47-53.
28. Dunlop BW, Thase ME, Wun CC, et al. A meta-analysis of factors impacting detection of antidepressant efficacy in clinical trials: the importance of academic sites. Neuropsychopharmacology. 2012;37(13):2830-2836.
29. Brody B, Leon AC, Kocsis JH. Antidepressant clinical trials and subject recruitment: just who are symptomatic volunteers? Am J Psychiatry. 2011;168(12):1245-1247.
30. Califf RM, Filerman GL, Murray RK, et al. The clinical trials enterprise in the United States: a call for disruptive innovation. National Academy of Sciences, Institute of Medicine Discussion Paper. http://www.iom.edu/∼/media/Files/Perspectives-Files/2012/Discussion-Papers/Drug%20Forum-Call%20for%20CTE.pdf. Updated April 13, 2012. Accessed July 22, 2014.
31. Thase ME, Larsen KG, Kennedy SH. Assessing the 'true' effect of active antidepressant therapy v placebo in major depressive disorder: use of a mixture model. Br J Psychiatry. 2011;199(6):501-507.
32. Papakostas GI. Limitations of contemporary antidepressants: tolerability. J Clin Psychiatry. 2007;68(suppl 10):11-17.
33. Lin EH, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care. 1995;33(1):67-74.
34. Hu XH, Bull SA, Hunkeler EM, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry. 2004;65(7):959-965.
35. Katona CL, Katona CP. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. Neuropsychiatr Dis Treat. 2014;10:349-354.
36. Boulenger J-P, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol. 2012;26(11):1408-1416.
37. Baldwin DS. Sexual dysfunction associated with antidepressant drugs. Expert Opin Drug Saf. 2004;3(5):457-470.
38. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002;63(4):357-366.
39. Henigsberg N, Mahableshwarkar AR, Jacobsen P, et al. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry. 2012;73(7):953-959.
40. Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol. 2012;22(7):482-491.
41. Mahableshwarkar AR, Jacobsen PL, Chen Y. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin. 2013;29(3):217-226.
42. Jain R, Mahableshwarkar AR, Jacobsen PL, et al. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol. 2013;16(2):313-321.
43. Montejo-González AL, Llorca G, Izquierdo JA, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther. 1997;23(3):176-194.
44. McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther. 2000;26(1):25-40.
45. Beronio K, Po R, Skopec L, et al. Affordable Care Act Will Expand Mental Health and Substance Use Disorder Benefits and Parity Protections for 62 Million Americans. Washington, DC: ASPE Research Brief, Office of the Assistant Secretary for Planning and Evaluation, US Dept of Health and Human Services; 2013.
46. Sturm R, Gresenz CR. Relations of income inequality and family income to chronic medical conditions and mental health disorders: national survey. BMJ. 2002;324(7328):20-23.
47. Lynch JW, Kaplan GA, Shema SJ. Cumulative impact of sustained economic hardship on physical, cognitive, psychological, and social functioning. N Engl J Med. 1997;337(26):1889-1895.
48. Lorant V, Deliège D, Eaton W, et al. Socioeconomic inequalities in depression: a meta-analysis. Am J Epidemiol. 2003;157(2):98-112.
49. Moussavi S, Chatterji S, Verdes E, et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007;370(9590):851-858.
50. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160(14):2101-2107.
51. Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med. 2000;160(21):3278-3285.
52. Agency for Healthcare Research and Quality. Patient-centered medical home resource center: defining the PCMH. http://www.pcmh.ahrq.gov/page/defining-pcmh. Accessed July 17, 2014.
53. Wexler R, Hefner J, Welker MJ, et al. Health care reform: possibilities & opportunities for primary care. J Fam Pract. 2014;63(6):298-304.
54. Robinson WD, Geske JA, Prest LA, et al. Depression treatment in primary care. J Am Board Fam Pract. 2005;18(2):79-86.